糖类抗原125在心力衰竭诊治中的价值
|
摘要
<正>心力衰竭(心衰)是所有心血管疾病的严重或终末阶段,是由于心脏结构或功能的变化导致心功能受损的一组复杂的临床综合征,主要表现为乏力、呼吸困难及液体潴留。然而,目前可指导心衰临床诊治的评价工具有限,且都有一定的局限性,需要更加简便、可靠、敏感的方法进一步完善心衰的诊治。近年来,国内外多项研究均表明糖类抗原125(CA125)血清水平的变化与心功能、超声心动图及血流动力学的参数改变密切相关,能很好地评估心衰病情、判断预后并指导治疗。1CA125的生物学特性及临床背景CA125分子量20万～100万,半衰期约4.8天,主要在
引文
[1] Miralles C, Orea M, Espana P, et al. Cancer antigen 125associated with multiple benign and malignant pathologies[J]. Ann Surg Oncol,2003,10(2):150.
[2] Nunez J, Nunez E, Consuegra L, et al. Carbohydrate antigen125:an emerging prognostic risk factor in acute heart failure?[J].Heart, 2007, 93(6):716.
[3]史金伟,岳天霞.慢性心衰患者C-反应蛋白、心肌肌钙蛋白I及糖类抗原CA125的检测结果[J].实用检验医师杂志,2016, 8(4):212.
[4]乔华,李国民,何胜虎.糖类抗原125对急性心力衰竭诊断及临床预后的预测作用[J].中国心血管杂志,2017, 22(3):186.
[5] Faggiano P,D'Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure[J]. Eur J Heart Fail, 2005, 7(1):57.
[6]代小娇,于健,李红玲,等.BNP与CA125在诊断急性心力衰竭中的临床价值[J].医学信息,2016, 29(11):63.
[7]张二苗,刘龙,王凌燕.CA125在冠心病所致充血性心力衰竭患者中的临床意义[J].中国实验诊断学,2017, 21(1):25.
[8] Huang F, Zhang K, Chen J, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion[J]. Clin Biochem,2013, 46(16-17):1694.
[9] Minana G, Nunez J, Sanchis J, et al. CA125 and immunoinflammatory activity in acute heart failure[J]. Int J Cardiol, 2010,145(3):547.
[10]孙伟莉,李卫鹏,袁媛,等.BNP与CA125检测在诊断慢性心力衰竭中的价值[J].中华全科医学,2011,9(10):1528.
[11]薛旸.老年心力衰竭患者糖类抗原125与B型利钠肽的变化和意义[J].国际心血管病杂志,2016, 43(1):58.
[12] N u nez J, Rabinovich GA,Sandino J,et al. Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure[J]. PLoS One, 2015, 10(4):e0122360.
[13]黄洁,刘国红,杨海英.血清CA125与慢性心力衰竭严重程度及近期预后相关性分析[J].标记免疫分析与临床,2017, 24(7):754.
[14] Nunez J, Nunez E, Bayes-GenisA, et al. Long-termserial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure[J]. Eur Heart J Acute Cardiovas Care, 2017,6(8):685.
[15]李学强,赵立坤.血清糖类抗原125对慢性心衰患者病情评估、疗效判定及预后预测价值的研究[J].中国现代医药杂志,2014, 16(5):47.
[16] Kaya H,Kurt R, Beton O,et al. Cancer Antigen 125 is Associated with Length of Stay in Patients with Acute Heart Failure[J].Tex Heart Ins J,2017, 44(1):22.
[17] Nunez J, Llacer P, Bertomeu-Gonzdlez V, et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure:CHANCE-HF A Randomized Study[J]. JACC Heart Fail, 2016,4(11):833.
[2] Nunez J, Nunez E, Consuegra L, et al. Carbohydrate antigen125:an emerging prognostic risk factor in acute heart failure?[J].Heart, 2007, 93(6):716.
[3]史金伟,岳天霞.慢性心衰患者C-反应蛋白、心肌肌钙蛋白I及糖类抗原CA125的检测结果[J].实用检验医师杂志,2016, 8(4):212.
[4]乔华,李国民,何胜虎.糖类抗原125对急性心力衰竭诊断及临床预后的预测作用[J].中国心血管杂志,2017, 22(3):186.
[5] Faggiano P,D'Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure[J]. Eur J Heart Fail, 2005, 7(1):57.
[6]代小娇,于健,李红玲,等.BNP与CA125在诊断急性心力衰竭中的临床价值[J].医学信息,2016, 29(11):63.
[7]张二苗,刘龙,王凌燕.CA125在冠心病所致充血性心力衰竭患者中的临床意义[J].中国实验诊断学,2017, 21(1):25.
[8] Huang F, Zhang K, Chen J, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion[J]. Clin Biochem,2013, 46(16-17):1694.
[9] Minana G, Nunez J, Sanchis J, et al. CA125 and immunoinflammatory activity in acute heart failure[J]. Int J Cardiol, 2010,145(3):547.
[10]孙伟莉,李卫鹏,袁媛,等.BNP与CA125检测在诊断慢性心力衰竭中的价值[J].中华全科医学,2011,9(10):1528.
[11]薛旸.老年心力衰竭患者糖类抗原125与B型利钠肽的变化和意义[J].国际心血管病杂志,2016, 43(1):58.
[12] N u nez J, Rabinovich GA,Sandino J,et al. Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure[J]. PLoS One, 2015, 10(4):e0122360.
[13]黄洁,刘国红,杨海英.血清CA125与慢性心力衰竭严重程度及近期预后相关性分析[J].标记免疫分析与临床,2017, 24(7):754.
[14] Nunez J, Nunez E, Bayes-GenisA, et al. Long-termserial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure[J]. Eur Heart J Acute Cardiovas Care, 2017,6(8):685.
[15]李学强,赵立坤.血清糖类抗原125对慢性心衰患者病情评估、疗效判定及预后预测价值的研究[J].中国现代医药杂志,2014, 16(5):47.
[16] Kaya H,Kurt R, Beton O,et al. Cancer Antigen 125 is Associated with Length of Stay in Patients with Acute Heart Failure[J].Tex Heart Ins J,2017, 44(1):22.
[17] Nunez J, Llacer P, Bertomeu-Gonzdlez V, et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure:CHANCE-HF A Randomized Study[J]. JACC Heart Fail, 2016,4(11):833.